Ovarian cancer remains the leading cause of death among diseases of the female genital organs. Absolute majority of patients with ovarian cancer stage lll-IV are admitted to oncological clinics. Determination of CA125 at ovarian cancer does not always solve the problem of early diagnosis; there is the necessity of finding new oncofatal antigens or combinations of markers.
Serum from 52 patients with diagnosed serous ovarian cancer was analyzed for CA-125 and HE4 levels in National Cancer Research Center of the Republic of Uzbekistan. From 52 patients in 10 patients was revealed stage IIIA process, in 9 patients - stage IIIB, in 22 patients - stage INC and in 11 patients - stage IV. The mean age of patients was 58.4 Â± 6.7 years. The level of tumor markers CA-125 and HE 4 determined before treatment and after treatment in the dynamics (8 to 32 months) every 3 months.
We studied the results of each tumor marker in univariate as well as multivariate analysis. Individually, the results were different, false-positive and false-negative values differed. Analysis of combined use of CA-125 and HE 4 showed that tumor markers complemented each other, the efficiency of detection of early recurrence or metastasis increased to 27.5% in a ratio of the use of each tumor marker individually (CA -125 for 31.2%, and HE 4 for 25.1%).
The use of CA-125 or HE 4 at ovarian cancer is not always specific and reasonably sensitive at early stages. The combination of CA-125 and HE 4 levels was significantly increased the efficiency of early detection of recurrences.
Clinical trial identification
All authors have declared no conflicts of interest.